| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net (loss) income | -3,753 | 13,438 | 17,673 | NaN |
| Depreciation and amortization | 2,584 | 2,657 | 8,281 | NaN |
| Stock-based compensation | 1,896 | 1,617 | 5,327 | NaN |
| Deferred income taxes | NaN | 3,245 | NaN | NaN |
| Provision for credit loss recovery | 0 | 0 | -362 | NaN |
| Loss on disposal of property and equipment | -6 | 0 | -4 | NaN |
| Loss on impairment of asset | NaN | 0 | NaN | NaN |
| Accounts receivable, net | -27,325 | 20,089 | 1,192 | NaN |
| Inventory, net | 3,178 | -3,961 | 752 | NaN |
| Prepaid expenses and other | -116 | 718 | -393 | NaN |
| Other current assets | -60 | 26 | 139 | NaN |
| Accounts payable | 3,110 | -1,330 | 877 | NaN |
| Operating lease assets and liabilities, net | 553 | 539 | 1,266 | NaN |
| Accrued expenses and other | -11,694 | 12,875 | 279 | NaN |
| Post-marketing commitment liability | -503 | -672 | -1,740 | NaN |
| Net cash provided by operating activities | 15,416 | 14,419 | 9,689 | 17,694 |
| Purchase of property and equipment | 0 | -36 | 26 | 81 |
| Purchase of available-for-sale securities | 24,863 | 46,937 | 26,784 | 34,420 |
| Maturity of available-for-sale securities | 27,337 | 19,924 | 27,316 | 24,784 |
| Purchase of intangible assets | NaN | 0 | NaN | NaN |
| Net cash provided by investing activities | 2,474 | -26,977 | 506 | -9,717 |
| Net proceeds from shares issued under employee stock plans | NaN | 0 | 0 | 130 |
| Payment of debt | 11,110 | 11,110 | 11,110 | 22,220 |
| Payment of exit costs | 222 | 222 | 222 | 444 |
| Net cash used in financing activities | -11,332 | -11,332 | -11,332 | -22,534 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 6,558 | -23,890 | -1,137 | -14,557 |
| Cash, cash equivalents and restricted cash, beginning of period | 31,726 | 55,616 | 71,310 | NaN |
| Cash, cash equivalents and restricted cash, end of period | 38,284 | 31,726 | 55,616 | NaN |
PUMA BIOTECHNOLOGY, INC. (PBYI)
PUMA BIOTECHNOLOGY, INC. (PBYI)